Erythromycin vs placebo
- Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 255 participantsVery low
It is very uncertain whether erythromycin changes all‐cause mortality compared with nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin changes visualisation of gastric mucosa compared with nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin changes NSAEs compared with nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin changes SAEs compared with placebo (very low certainty).
It is very uncertain whether erythromycin changes rebleeding compared with nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin changes all‐cause mortality compared with placebo (very low certainty).
It is very uncertain whether erythromycin changes NSAEs compared with placebo (very low certainty).
It is very uncertain whether erythromycin changes rebleeding compared with placebo (very low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes all‐cause mortality compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes NSAEs compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes rebleeding compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
The review found no eligible studies for this question.